Vol 58, No 4 (2007)
Review paper
Published online: 2007-05-17

open access

Page views 582
Article views/downloads 1225
Get Citation

Connect on Social Media

Connect on Social Media

Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly

Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyżanowska-Świniarska, Andrzej Lewiński, Elżbieta Łomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyński
Endokrynol Pol 2007;58(4):350-353.

Abstract

Consensus statement of the Polish Society of Endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then 30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets: biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction, inhibition of tumor growth). The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow objective evaluation of long-term efficacy of the treatment.
(Pol J Endocrinol 2007; 58 (4): 350-355)

Article available in PDF format

View PDF (Polish) Download PDF file